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Among the common complication of cirrhosis portal hyperten-
sion witnessed a major improvement of prognosis during the past
decades. Principally due to the introduction of rational treat-
ments based on new pathophysiological paradigms (concepts of
thought) developed in the 1980s. The best example being the
use of non-selective beta-blockers and of vasopressin analogs,
somatostatin, and its analogs. Further reﬁnement in the knowl-
edge of the molecular mechanisms involved in the regulation of
both the splanchnic and hepatic circulation has led to the emer-
gence of new treatments, which are based on evidence that show
not only structural but also vasoactive components increase the
hepatic vascular resistance, as well as of angiogenesis. This
knowledge and future improvements will most likely result in
more effective treatment of portal hypertension and effective
prevention of its complications in early stages.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Portal hypertension is a frequent clinical syndrome that is
characterized by an increased portal venous pressure. This
results in an increase of the pressure gradient between the
portal vein and the inferior vena cava above the normal valuesJournal of Hepatology 20
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endothelial growth factor; PVL, portal vein ligation.(1–5 mmHg). Portal hypertension is most commonly caused by
chronic liver disease, followed by schistosomiasis and by pre-
hepatic portal vein occlusion. The latter two conditions are
particularly common in North Africa, Asia and Amazonia. The
relevance of portal hypertension is well illustrated by the fact
that in patients with cirrhosis of the liver, portal hypertension
is the main cause of death and of liver transplantation. Only
in Europe it is estimated that 29 million patients suffer from
chronic liver disease, and that 170,000 die each year from
complications of cirrhosis, a number exceeding the mortality
due to breast cancer [1].
The knowledge of the pathophysiology of portal hyperten-
sion has changed dramatically during the past decades due
to the combination of the availability of new methods for clin-
ical evaluation, the introduction of reliable experimental mod-
els and the application of recent advances in cellular,
molecular, and systems biology. Another important recent con-
cept is that for the complications of portal hypertension to
occur, the portal pressure should increase above a critical
threshold value of 10 mmHg that deﬁnes what is known as
clinically signiﬁcant portal hypertension [2]. Implicit in this
concept is that if we can prevent the portal pressure gradient
to exceed >10 mmHg, we would be able to prevent all the
complications of portal hypertension and the decompensation
of cirrhosis [3]. Variceal bleeding and ascites rarely, if ever,
occur until the portal pressure gradient increases above
12 mmHg, indicating a level of absolute protection we strive
to achieve during therapy [4]; while recognizing that marked
reductions of the risk of variceal bleeding/rebleeding and of
spontaneous bacterial peritonitis can be achieved with less
marked reductions of the portal pressure gradient [5–8]. This
improved knowledge of the mechanisms of portal hyperten-
sion and of the haemodynamic targets to reach in therapy
has led to the development of new treatments for portal
hypertension that have resulted in a marked improvement of
prognosis [2].
It is predicted that application of new concepts arising from
current research will contribute to further advances in therapy.
This review offers a detailed account of this changing panorama,
focusing in cirrhotic portal hypertension and indicating how the
advances in understanding have led to new successful therapies.15 vol. 62 j S121–S130
ReviewKey Points 
• Portal hypertension is the most common and severe 
complication in patients with cirrhosis, representing the 
first cause of death or need for liver transplantation
• Changes in the understanding of the pathophysiology of 
portal hypertension has allowed the introduction of new 
effective treatments
• The old pathophysiological view considered that 
increased resistance to portal flow through the cirrhotic 
liver resulted in reduced portal flow and congested 
splanchnic circulation, with porta-caval shunts being the 
mainstay of therapy
• Demonstration of increased portal blood inflow, 
splanchnic vasodilation and hyperdynamic circulation 
as important contributors to portal hypertension lead 
to the introduction of vasoconstrictors (terlipressin, 
somatostatin and analogs), and of nonselective beta-
blockers for the treatment and prevention of variceal 
bleeding, with a progressive and dramatic decrease in 
its incidence and mortality
• Recent advances in the knowledge of the molecular 
mechanisms regulating hepatic vascular tone, 
endothelial dysfunction, and its relationship with 
fibrogenesis, angiogenesis and hepatic vascular 
occlusion/thrombosis is the basis of current emerging 
therapies for portal hypertensionTime Paradigm
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The ﬁrst concept that needs to be stressed when considering the
pathophysiology of portal hypertension is that according to the
hemodynamic application of Ohm’s Law, the portal pressure gra-
dient (DP) is directly proportional to the amount of blood ﬂow
circulating through the portal venous system (Q) and the resis-
tance opposing this ﬂow (R) (DP = Q  R). Therefore, from a the-
oretical point of view, an increase in portal pressure can be
considered as secondary to an increase in resistance, to an
increase in blood ﬂow, or to a combination of both factors.
The history of portal hypertension can be divided in two dis-
tinct periods, during which the pathophysiology of portal hyper-
tension has been dominated by two opposing concepts. In the
past, initiated in the times of Hippocrates (Cos, 460 BC) and Galen
(160 AD) and continued well into the 20th century, it was consid-
ered that portal hypertension was a result of ‘‘congestion’’ of the
portal circulation due to increased resistance to portal blood ﬂow
through the hard cirrhotic liver. Present times initiated with the
papers of Groszmann and Cohn [9,10] describing that despite
the increased resistance to blood ﬂow through the cirrhotic liver,
the splanchnic circulation in portal hypertension was not con-
gested, but hyperemic. These contrasting views were the basis
for two radically different approaches for portal hypertension:
while the traditional ‘‘congestive’’ hypothesis led to the introduc-
tion and wide use of surgical porta-caval shunts (and of other
operations such as the meso-caval and the spleno-renal shunts),
the demonstration that an increased blood ﬂow plays a critical
role in provoking advanced portal hypertension led to modern
therapies, based on the use of splanchnic vasoconstrictors
(terlipressin, somatostatin and its derivatives) [11,12] and of
non-selective beta-blockers [13] to decrease portal-collateral
blood ﬂow and hence portal pressure.Therapeutic applications
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The next change in the way of understanding the patho-
physiology of portal hypertension was shown by Bathal and
Grossmann [14] that the increased hepatic resistance to portal
blood ﬂow through the cirrhotic liver was not only a mechanical
consequence of the architectural disruption of the liver vascular
anatomy caused by ﬁbrosis and nodule formation, but that
together with this structural component there was a dynamic
component due to an increased hepatic vascular tone. The
authors further demonstrated that the dynamic component of
increased liver resistance could be due to a deﬁcit of vasodilatory
substances (as it was corrected by nitroprusside) and/or to exces-
sive production of vasoconstrictors, which could account for
about one third of the increased hepatic resistance causing portal
hypertension in cirrhosis. Thus, targeting this increased resis-
tance could allow for achieving over a 30% decrease in portal
pressure in cirrhosis [11,12]. Subsequent developments demon-
strated the role of deﬁcient nitric oxide (NO) availability. The
cause of this dynamic component arises from endothelial dys-
function at the hepatic sinusoidal cells [15], the role of contrac-
tion of activated hepatic pericyte-like stellate [16], the
implication of prostanoids and other vasoconstrictors [17,18],
and the possibility of improving hepatic endothelial dysfunction
by a variety of strategies [19–26].
In parallel with these developments, a better knowledge of
the crosstalk between hepatic sinusoidal endothelial cells and
hepatic stellate cells (HSC), and its implications in terms of acti-
vating ﬁbrogenesis and angiogenesis [27–29] opened new per-
spectives, pointing out that ﬁbrogenesis in cirrhosis can be
modulated by acting on etiologic factors, collagen metabolism,
on angiogenesis, and on endothelial dysfunction (separately or
in combination) [30]. In addition, observations on pathology spe-
cimens disclosed the importance of vascular occlusion in the liver
in progression of parenchymal extinction lesions [31]. Together
with the emerging new concept that cirrhosis could be consid-
ered a prothrombotic condition have led to the proposal that
anticoagulants may slow or prevent progression of cirrhosis [32].
The following sections are devoted to analysing these
concepts.Intrahepatic circulation and cirrhosis. Description of structural
and functional changes
A number of protean changes are manifested in the hepatic sinu-
soids during the process of advanced liver injury and cirrhosis
development [33]. Even hepatocyte plasma membrane adjacent
to the sinusoid undergoes some of these changes including loss
of microvilli, but the most prominent changes occur within the
sinusoidal cells themselves, including the sinusoidal endothelial
cell and HSC. Sinusoidal endothelial cells normally contain fenes-
trae organized in sieve plates. These are thought to facilitate the
transport of macromolecules from the sinusoidal lumen to the
abluminal hepatocytes. In response to injury and early cirrhosis
development, these fenestrae are lost. The endothelial cells them-
selves also undergo dramatic reprogramming in terms of their
functional phenotype and angiocrine signaling pathways, which
will be reviewed further below.
The HSC also undergo changes. Under basal conditions, the
cell resides largely as a vitamin A, lipid storing cell. It is contro-
versial whether it has contractile properties under basal condi-
tions, but in view of the low resistance sinusoids under normalJournal of Hepatology 2015conditions, the contractile effects of stellate cells under normal
conditions are probably not required to be prominent [34]. How-
ever, in response to liver injury, a number of changes occur which
have been referred to broadly as HSC ‘‘activation’’ [16]. This
includes alterations in almost every phenotype of the cell, and
can be summarized as an increase in contractility, migratory
capacity, matrix deposition, and proﬁle change in the release of
paracrine factors. Some new aspects of the activation process
are also discussed later in the review.
These changes in the molecular phenotypes of the sinusoidal
cells result in dramatic pathophysiological alterations in the
structure and function of the hepatic sinusoids. These changes
also lead to the increased deposition of matrix proteins within
the hepatic sinusoids and increased contractility of the perisinu-
soidal cells and ensuing constriction of the sinusoids themselves.
While earlier concepts focus on the effects of the matrix on portal
hypertension through pure mechanical phenomenon, evolution
in thought has led to the understanding that the increase in vas-
cular resistance also contributes importantly to increased intra-
hepatic resistance in portal hypertension [33]. Varying studies
show that this component could be in the range of 30% to 40%
of increased intrahepatic resistance. However, in reality, there
is probably an important interplay between these mechanical
and vascular components, since many of the matrix proteins have
very important effects on sinusoidal cells that ultimately regulate
the vascular phenotype as well, most notably including matrix
proteins such as ﬁbronectin, discussed below. This combination
of changes to both mechanical and vascular components in the
sinusoids has been referred to as pathological sinusoidal remod-
elling [35]. Thus, ultimately, the changes that occur in the hepatic
sinusoids in response to advanced liver injury and cirrhosis result
in increased intrahepatic vascular resistance from a combination
of effects of matrix changes and tonicity changes. Of which, have
been described in detail in prior reviews, and the remainder of
this review will focus on new ideas in the molecular pathobiology
of hepatic sinusoids.New paradigms in the molecular pathobiology of the hepatic
sinusoids (Fig. 2)
A number of new concepts are emerging in the molecular patho-
biology of the hepatic sinusoids and how the changes affect
development of portal hypertension. While all of these cannot
be reviewed comprehensively here, some examples are outlined
below.
Sinusoidal endothelial cell
The role of the sinusoidal endothelial cell in portal hypertension
development continues to evolve with increasing evidence sup-
porting its importance in this process. Studies from the last two
decades now clearly show that the sinusoidal endothelial cell
contributes considerably to increased intrahepatic resistance in
portal hypertension development [33]. This is an important
observation since prior to that, the cells were viewed largely as
serving a passive role for macromolecular transport across the
sinusoids. Since these initial observations, the role of the
endothelial cell in portal hypertension development continues
to grow [34]. The concept of endothelial dysfunction highlights
the impaired release of vasodilatory molecules from sinusoidalvol. 62 j S121–S130 S123
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Fig. 2. Newer molecular paradigms in the sinusoids in cirrhosis. Boxed area is
a higher magniﬁcation cartoon depiction of potential molecular events within the
sinusoids during cirrhosis. The cartoon shows crosstalk between sinusoidal
endothelial cells (SEC), macrophage (M), and hepatic stellate cells (HSC). Selected
signal pathways under active investigation are depicted including innate
immunity through toll like receptors (TLR), traditional inﬂammatory molecules,
angiocrine signals, and matrix such as ﬁbronectin. Potential effects of thrombus
are also shown.
Reviewendothelial cells during liver injury progression. This is most
notably characterized by diminished production of the potent
vasodilator, NO, occurring through a number of post-translational
actions produced by endothelial NO synthase (eNOS) [36,37]. This
is also accompanied by an increase in vasoconstrictive molecular
release, such as endothelin proteins. A number of other
vasoregulatory molecules have also been implicated in this pro-
cess. While several therapeutic modalities to alleviate endothelial
dysfunction have been evaluated in animal models and in
humans including various NO donor compounds, the compounds
receiving most attention recently for potential therapeutic bene-
ﬁts are the statin class of drugs [19,38,39].
Over the last several years, the role of angiogenesis in the hep-
atic sinusoids has also been elucidated [35,40,41]. Angiogenesis is
deﬁned as the growth and proliferation of existing endothelial
cells and has been implicated not only in increased intrahepatic
resistance in the sinusoids but also in the process of ﬁbrosis
development. The precise relationship between angiogenesis
and increased intrahepatic resistance and ﬁbrogenesis remain
ill-deﬁned, but may well relate to angiocrine signaling that is
associated with angiogenic endothelial cells [42,43]. This angio-
crine signaling likely regulates the phenotype of a number of
other cells in the sinusoid, most notably the hepatic stellate cell,
and it has been postulated that angiogenic endothelial cells may
stimulate HSC activation. However, there are a number of com-
plexities to this concept that may ultimately require consid-
eration in terms of potential therapies. For example, some
angiocrine signals also maintain HSC quiescence as discussed fur-
ther below [28]. Additionally, while angiogenesis and angiogenicS124 Journal of Hepatology 2015molecules appear to be important in the development of
increased intrahepatic resistance and early ﬁbrosis, these same
molecules may also be important in resolution of liver injury
and resolution of early ﬁbrosis. One example is vascular endothe-
lial growth factor (VEGF), a potent angiogenic molecule that may
also contribute to HSC activation [44]. However, VEGF may con-
versely facilitate resolution of early liver injury through the
recruitment of macrophages, which are required for resolution
steps in early cirrhosis [45].
Another interesting and evolving concept pertaining to sinu-
soidal endothelial cells relates to capillarization. Although capil-
larization was described by Fenton and Schaffner several
decades ago, its role continues to be revisited [33]. Capillarization
refers to the deposition of basement membrane and other matrix
proteins as well as the changes in sinusoidal endothelial structure
that occur during early ﬁbrosis. Recent work suggests that these
changes may play a very important pathogenic role in the subse-
quent steps of liver ﬁbrosis and highlight the potential role of the
sinusoidal endothelial cell as a very early player, not only in
increased intrahepatic resistance, but in liver injury and ﬁbrosis
itself [28,46].
Hepatic stellate cell
A number of important ideas are also evolving relating to the HSC
in portal hypertension development. While the molecular biology
of the HSC activation process continues to grow at a rapid pace
[16,47], one of the notable evolutions pertaining to the HSC has
been the identiﬁcation of these cells as innate immune cells. A
number of seminal studies have outlined that agonists of innate
immune receptors including toll-like receptor 4 (TLR4) lead to
hepatic stellate cell activation, which is key for sinusoidal con-
striction as well as deposition of matrix proteins [48,49]. This is
particularly important since lipopolysaccharide is a canonical
ligand for TLR4, and the lipopolysaccharide derived from the
gut lumen has long been implicated in the processes of liver
injury, ﬁbrosis, and portal hypertension development [50,51].
Although not reviewed extensively here, the involvement of the
traditional innate immune cell in the hepatic sinusoid, the Kupf-
fer cell, continues to grow in its role in portal hypertension. Inter-
estingly, a number of other ligands for the TLRs reside within the
hepatic sinusoids and are released by injured cells within the liv-
er. One such ligand example is HMGB1, which is released by
injured cells in response to various insults including alcoholic liv-
er injury [52]. Thus, the innate immune function of the HSC can
contribute to the portal hypertension phenotype through not
only gut-derived ligands of TLR4 but also through ligands that
are released by injured cells within the liver itself.
It should be noted that the expanding role of innate immune
signaling in HSC is only one example of a broader recognition of
the role of inﬂammation in portal hypertension (as well as in
acute on chronic liver failure) which involves multiple cell types,
molecules, and processes. This concept is leading to changes in
therapy. For example, speciﬁc antibiotics are already used to
combat bacterial translocation and newly developed TLR antago-
nists are working their way through early phase development.
The broader link of inﬂammation with portal hypertension was
recently reviewed by Mehta et al. [53] and therefore not expand-
ed in more detail here.
Signaling pathways in HSC continue to be an area of active
investigation and are important not only for academic interestvol. 62 j S121–S130
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but more importantly because speciﬁcity of potential therapies
will be determined by the targeting of signals in a speciﬁc man-
ner. In this regard, the renin-angiotensin system continues to be
actively investigated not only in HSC but also in the splanchnic
circulation [74,38]. Calcium signaling also continues to be of
interest in HSC with calcium independent pathways being
involved in both contraction and matrix deposition by HSC [38].
Matrix
As mentioned earlier, the release of matrix proteins by HSC is
likely to contribute to increased intrahepatic resistance not only
through the mechanical effects of the matrix but also through sig-
naling actions. One prototypical protein that ﬁts this idea is
ﬁbronectin [54,55]. Fibronectin is released by a number of cells
within the liver and requires ﬁbrillation of soluble ﬁbronectin
in order for this molecule to develop into deposited matrix pro-
tein. Upon its deposition, it has very important effects on a num-
ber of cell types including HSC and sinusoidal endothelial cells,
and consequently leads to what could be described as an activa-
tion phenotype of both of these cells. Further study is required
into the potential signaling effects of a number of other matrix
proteins, especially early matrix proteins that are deposited by
injured cells during early cirrhosis.
Thrombus
The role of thrombosis is undergoing important changes in
thought as well in terms of its effects on portal hypertension
development. This includes the increased recognition that cirrho-
sis in portal hypertension patients may actually show evidence of
increased thrombosis rather than increased bleeding as was ini-
tially thought [56]. This is important within the intrahepatic
sinusoids because increasing evidence shows that microthrombi
within the sinusoids could propagate increased intrahepatic
resistance liver injury and ﬁbrosis development [57]. While this
is most notable in forms of intrahepatic congestion such as
Budd-Chiari Syndrome and cardiac cirrhosis, it may also be rele-
vant in other forms of cirrhosis and portal hypertension as well.
Indeed, this was postulated a while back by studies of human
pathology specimens that showed parenchymal extinction due
to microthrombi [31]. Much more work is needed in this area,
but a number of pharmacological changes to management could
be implied if thrombus plays an affect in the role of ﬁbrosis devel-
opment. A clinical paper showing potential beneﬁcial effects of
enoxaparin in subgroups of patients with cirrhosis supports this
concept [32].
Extracellular vesicles
Another evolving concept in sinusoidal structure and phenotype
in cirrhosis and portal hypertension development relates to
mechanisms by which cells signal with each other. While tradi-
tional concepts have focused on the paracrine release of mole-
cules that act on adjacent cells in the sinusoid, increasing
evidence shows important roles of extracellular vesicles in the
signaling models. Extracellular vesicles include exosomes,
microparticles, and apoptotic bodies. While this has been
reviewed previously, a number of recent studies show that these
extracellular vesicles may be quite important in portal hyperten-
sion pathobiology [58–60]. The reasons for this include theJournal of Hepatology 2015opportunity for released proteins to maintain stability within
the vasculature for longer distances due to their protection with-
in the extracellular vesicle. Ongoing studies aim to understand
which proteins may signal through traditional paracrine path-
ways vs. pathways involving extracellular vesicles and the speci-
ﬁc mechanisms by which extracellular vesicles could achieve
their signaling actions.
Thus, a strong blueprint has been developed as to how the
sinusoids contribute to portal hypertension through an increase
of hepatic resistance. While carvedilol is one compound that
exempliﬁes this concept owing to its alpha antagonistic proper-
ties that vasodilate sinusoids and thus partially contribute to
the mechanism of action of this beta blocker [61–63], other com-
pounds such as the statin class of drugs is undergoing further
evaluation as well. This is an important shift in concepts from
initial thinking that the sinusoids were simply an inert vascular
bed that lacked vasoregulatory function. Many more molecular
elucidations have occurred over the past decades and a number
of new and evolving concepts continue to move these ideas
forward.The splanchnic and systemic circulation in portal hypertension
Pathophysiology
In 1953, based on the clinical observation that patients with cir-
rhosis frequently showed ‘‘warm extremities, cutaneous vascular
spiders, wide pulse pressure, and capillary pulsations in the nail
beds,’’ Kowalski and Abelmann [64] ﬁrst showed that cirrhosis
is associated with a hyperdynamic circulatory syndrome charac-
terized by an increase in cardiac output and a decrease in periph-
eral vascular resistance. This syndrome, although commonly
recognized as a complication of cirrhosis, could be better concep-
tualized as a complication of portal hypertension since it has
been observed in all forms of portal hypertension caused by con-
ditions other than cirrhosis and conﬁrmed in different
experimental models of portal hypertension.
These ﬁndings were reproduced in subsequent studies; how-
ever, the recognition of the harmful effect of this syndrome on
multiple organs was only recognized years later [65]. We now
know that the multi-organ failure observed in terminal chronic
liver diseases is in part attributable to this progressive vasodilata-
tion. The harmful effects observed in the systemic circulation and
several other vital organs always originated via the vasodilatory
state. Whereas in the heart, the splanchnic, the pulmonary, and
the cerebral circulation, these deleterious effects are mediated
by the vasodilatation itself, in other organs such as the kidneys
it is a response to vasodilatation in the other circulatory beds.
Over the years we have learned that patients are hyperdynamic
before the syndrome becomes clinically evident.
The systemic circulatory hyperdynamic syndrome seems sec-
ondary to changes occurring in regional vascular beds. Any
change in peripheral vascular resistance is rapidly compensated
by changes in cardiac output [66]. We believe that the initial
vasodilatation occurs in the splanchnic circulation and that the
heart response is directly related to a combination of splanchnic
vasodilatation and expansion of the plasma volume, together
with an increased venous return to the heart, in large part,
through portal-systemic shunts. Despite these ﬁndings, for many
years the dominant theory to explain portal hypertension invol. 62 j S121–S130 S125
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cirrhosis still was the ‘backward ﬂow’ theory, which postulated
that increased resistance was the only cause for the increase in
portal pressure and predicted a splanchnic hypodynamic circula-
tion, with increased mesenteric vascular resistance. This theory
was supported by the ﬁnding of a decreased portal ﬂow at the
hepatic hilum [67]. However, these data were misleading, since
it did not take into account the ﬂow that is diverted through
the collateral circulation. In the 1970s a series of studies by
Groszmann and Cohn in patients with liver cirrhosis suggested
that the splanchnic circulation was hyperdynamic [68]. However,
in the portal vein constricted model (PVL) before getting hyper-
dynamic a hypodynamic period is observed early in the evolution
of portal hypertension [69]. This hypodynamic splanchnic circu-
lation, most likely is observed also in early cirrhosis when portal
hypertension is mainly attributable to an increase in intrahepatic
vascular resistance, and portal-systemic collaterals have not yet
developed. It is probable that during this stage, hypoxia develops
in the splanchnic bed triggering an angiogenic response [70] that
leads to the development of portal-systemic collaterals and the
hyperdynamic circulation.
In the 1980s a series of studies in animal models of portal
hypertension allowed us to fully characterize the hemodynamic
events that follow the induction of portal hypertension. These
studies allowed unequivocal demonstration that, after a short ini-
tial period of a hypodynamic splanchnic circulation, portal hyper-
tension transforms the circulatory splanchnic bed into a
hyperdynamic circulatory state, which contributes to the severity
of portal hypertension [69]. This has been called the ‘forward
ﬂow’ theory and set the rationale for the use of splanchnic vaso-
constrictors in patients with portal hypertension.
The PVL model develops massive portal-systemic shunting
and a hyperdynamic circulatory state as early as 4 days after
the induction of portal hypertension [69]. This model proved
extremely useful to study the hyperdynamic syndrome, since
most of the ﬁndings in the PVL model were subsequently repro-
duced in models of cirrhosis [70]. In patients with the hyperdy-
namic syndrome the cardiac index is usually higher than
normal (>4 L/min/m2). However, it is obviously insufﬁcient to
maintain arterial pressure on the face of progressive vasodilation.Molecular pathophysiology
Vasodilatation
Vasodilatation is a key component of the hyperdynamic syn-
drome. A wide variety of vasodilatory molecules play a role in
inducing the vasodilatory state. However, of all these molecules
NO is the most important [71]. The initial mechanisms and the
magnitude of increase in portal pressure required to trigger NO
production was deﬁned by studying systemic and splanchnic
hemodynamics, eNOS and VEGF expression in rats with different
degrees of portal hypertension (PVL) and portal-systemic shunt-
ing [72]. Compared with sham rats, all PVL rats exhibited features
of hyperdynamic circulation. Rats with minimal portal hyperten-
sion showed an early increase in VEGF and eNOS expression
selectively at the jejunum. Inhibition of VEGF signaling markedly
attenuated the increase in eNOS expression. In conclusion, mild
increases in portal pressure are enough to upregulate eNOS at
the intestinal microcirculation, and this occurs, at least in part,
through VEGF upregulation. Thus, unlike the intrahepatic circula-
tion, there is an excess of local NO production, which is associat-
ed with decreased responsiveness of the mesenteric circulation toS126 Journal of Hepatology 2015vasoconstrictors. NO causes vasodilatation through stimulation
of soluble guanylyl cyclase to generate cGMP in vascular smooth
muscle cells. NO also contributes to increase splanchnic blood
ﬂow by facilitating angiogenesis [73]. The eNOS signaling path-
way is activated in portal hypertension by numerous endothelial
cell stimuli. They include VEGF, angiotensin (1–7) (through a Mas
Receptor) [74] shear stress and inﬂammatory cytokines [75,76],
and regulated through a variety of mechanisms, including the
bacterial translocation1 mediated upregulation of GTP-cyclohy-
drolase I, which generates eNOS through increases in the cofactor
tetrahydrobiopterin [75]. The participation of inducible NOS has
also been reported during decompensated cirrhosis [76]. Other
vasodilators that have been also associated with the hyperdy-
namic syndrome are carbon monoxide, prostacyclins, anan-
damide, endocannabinoids, neuropeptides, endothelium-derived
hyperpolarizing factor, glucagon, vaso-intestinal peptide and
others [75].
Angiogenesis
In addition to VEGF several angiogenic factors are upregulated in
the splanchnic vascular bed of portal hypertensive subjects,
among these are the placental growth factor and the platelet
derived growth factor [75]. Angiogenesis and vasodilatation go
‘‘hand in hand’’ feeding each other. The same VEGF that regulates
the development of portal-systemic collaterals [77] (see section
on formation of collaterals and varices below) modulates the
increase in eNOS that leads to splanchnic vasodilatation [77]. It
is most likely a combination of circulatory hypoxia [78] and cir-
cumferential wall stress, which is initiated by early increase in
portal pressure, and leads to sequential events that induces the
hyperdynamic state.
An endogenous inhibitor of angiogenesis, Vasohibin-1, was
recently described to be selectively induced by the pro-angio-
genic growth factor VEGF as a consequence of a speciﬁc negative
feedback regulatory mechanism of pathological angiogenesis.
Vasoinhibin-1 reduces VEGF production to an intermediate
steady-state level sufﬁcient to maintain vascular homeostasis or
physiological angiogenesis associated with wound healing, but
not to drive pathological angiogenesis, diminishing the hemody-
namic abnormalities and portal pressure in a model of liver cir-
rhosis [79].
Formation and rupture of varices
Oesophageal and gastric varices are the more relevant portal-sys-
temic collaterals that develop in portal hypertension, as they are
responsible for one of its more representative and severe compli-
cations, massive acute gastrointestinal bleeding. Other conse-
quences of portal-systemic collaterals are linked to the
shunting of portal blood to the systemic circulation, and include
portal-systemic or hepatic encephalopathy, exacerbation of liver
failure, loss of ﬁrst pass effect for orally administered drugs,
abnormal metabolism of endo and xenobiotics, increased suscep-
tibility to sepsis, and exacerbation of the hyperkinetic circulation
and its consequences. We will focus here on the mechanisms
leading to the formation and bleeding of varices.
Oesophageal and gastric varices are formed by a conjunction
of anatomical, physical and biological factors. The traditional con-
cept was that collaterals develop by the opening and dilatation of
pre-existent vessels at sites of embryonic connection between
the portal and systemic circulations due to the increased portalvol. 62 j S121–S130
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pressure. Some of these collaterals evolve into varicose veins
through peculiar anatomical conditions of the esophageal venous
circulation. Portal hypertension triggers the dilatation of submu-
cosal veins, which become varicose, due to the incompetency in
the perforating communicating veins connecting the submucosal
and peri-esophagel veins. The lack of external tissue support and
the negative intra-esophageal pressure during inspiration would
further favour dilatation of the dilated submucosal veins and con-
tribute to the progressive increase in size of the oesophageal
varices [80]. This traditional view was challenged when Fernán-
dez et al. [77] reported for the ﬁrst time that formation of por-
tal-systemic collaterals in portal hypertension was modulated
by active angiogenesis. Speciﬁcally they were under the control
of the VEGF signaling cascade, to the point that interfering with
VEGF, either by means of monoclonal antibodies anti-VEGF
receptor 2, or upstream in VEGF production, resulted in >50%
inhibition of collateral formation, independently from modifying
portal pressure. These authors have since documented not only
inhibition of collateral formation, but also regression of already
formed collaterals under the combined inhibition of VEGF and
platelet derived grow factor or using the multi-kinase inhibitor
sorafenib [81,82]. Other implications of angiogenesis in portal
hypertension, including its effects on mesenteric hyperemia, liver
ﬁbrosis, inﬂammation and angiogenesis are reviewed in the pre-
ceding section.
This new way of conceiving collateral formation/regression
has led to proposing angiogenesis as a new target for the treat-
ment of portal hypertension.Rupture of varices
The mechanism of variceal bleeding was thought to be due to the
erosion of the thin wall of the varices as a consequence of gas-
troesophageal reﬂux, facilitated by the trauma from swallowing
solid food. However, this hypothesis was abandoned almost
30 years ago due to the lack of objective supportive evidence,
either from physiological studies or from the pathological
examination of the oesophageal mucosa in patients dying from
variceal bleeding. This was substituted by the so called ‘‘explo-
sion’’ theory that proposes that the varices bleed due to rupturing
of the thin walls caused by an exertion of tension beyond the ves-
sels elastic limit. According to Laplace’s law, variceal wall tension
(Wt) is deﬁned by the equation:
Wt ¼ ðPv PoÞ  r=t
In this equation, Pv is the intravariceal pressure (determined
by the increased portal pressure), Po is the pressure in the oeso-
phageal lumen, r is the radius of the varix, and t the thickness of
its wall. Therefore, wall tension increases with increased portal
pressure and this effect is multiplied by increased variceal size
and decreased variceal wall thickness [80,83]. This view explains
the prognostic value of the variceal risk factors: Child-Pugh C
class correlates well with a higher portal pressure; big variceal
size implies a greater diameter, and endoscopic red colour signs
probably reﬂect areas of decreased variceal wall thickness. Final-
ly, the oesophageal luminal pressure is lower than intra-ab-
dominal pressure and becomes negative during inspiration,
together with the lack of external tissue support explains why
oesophageal varices are more likely to bleed than other portal-
systemic collaterals.Journal of Hepatology 2015The hepatic arterial system
Under normal circumstances approximately 25% of the cardiac
output perfuse the liver. A third of this ﬂow is contributed by
the hepatic artery and the remainder by the portal vein [84].
The portal system is thought to be a passive vascular bed. Where-
as decreased ﬂow in the hepatic artery leads to a compensatory
reduction in vascular resistance, decreased portal ﬂow leads to
a reduction in the cross-sectional area of the portal vasculature
and a corresponding increase in portal venous resistance. Con-
versely, increased portal ﬂow, by inducing passive dilatation of
the vessel, leads to a passive decrease in portal vein resistance
[85]. Moreover, there is no portal venous hyperaemia in response
to decreased hepatic arterial ﬂow [85]. This contrasts with the
behaviour of the hepatic artery in response to decreased portal
ﬂow.
It has been known for many years that a reduction in portal
ﬂow results in an increase in hepatic arterial ﬂow [85]. Following
porta-caval anastomosis, the prognosis for recovery appears to
correlate with the increase in arterial ﬂow which follows diver-
sion of portal blood ﬂow [86]. The capacity of the hepatic artery
to increase its ﬂow in response to decreased portal ﬂow ranges
from 22% to 100%. In situations of hemodynamic compromise
such as haemorrhage, total hepatic blood ﬂow is not restored to
normal by hepatic arterial hyperemia. However this phenomenon
nevertheless has physiological importance, it tends to compen-
sate total hepatic blood ﬂow [85]. Arterial ﬂow to the liver is
not determined by oxygen demand. Under normal conditions,
the liver extracts less than 50% of the supplied oxygen. Under
conditions of increased oxygen demand, the liver augments its
oxygen extraction rather than increasing arterial ﬂow. In chronic
alcohol-fed rats, oxygen requirement by the liver increases dra-
matically (45%) without increased hepatic arterial ﬂow [87].
The hepatic artery, not part of the portal system, but also
seems to play an important role in the development and mainte-
nance of portal hypertension, was shown in the study by Zipprich
et al. [88]. The liver has a dual blood supply and the drainage of
the hepatic arterial blood into the sinusoids is at the beginning
of the sinusoidal network (zone 1). In cirrhosis a hyperdynamic
syndrome also develops in the hepatic arterial circulatory bed.
In response to the progressive loss in portal ﬂow caused by the
development of portal-systemic collaterals, the hepatic artery
vasodilates, increases its ﬂow and its participation in the mainte-
nance of portal hypertension [88]. This hyperdynamic hepatic
arterial syndrome is accentuated with the progression of chronic
liver diseases. This hepatic arterial response to the progressive
decrease in portal ﬂow is initiated and perpetuated by a complex
interaction of anatomical and functional factors and, contrary to
what is observed in the intrahepatic portal system, an excess pro-
duction of NO seems to play a role in the vasodilatation observed
[89].
The vascular resistance of the hepatic artery is determined in
the presinusoidal area, i.e. in the small hepatic branches before
draining into the sinusoids. Studies in an isolated rat liver perfu-
sion model of hepatic artery and portal vein observed that
changes in the hepatic artery perfusion lead to changes in the
sinusoidal and subsequently in the portal venous vascular resis-
tance [88]. The mechanisms involved in this decreased vascular
resistance in cirrhosis are not completely understood. It has been
postulated to be due to increased levels of NO in the presinu-
soidal area where the ﬁnal branches of the hepatic artery arevol. 62 j S121–S130 S127
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located [89]. The local increase of vasodilators, together with the
low arterial pressure, leads to a lower vascular resistance of the
hepatic artery. On the other hand, it has been shown that the
regulation of the hepatic arterial ﬂow, and especially the hepatic
arterial buffer response, is regulated by adenosine [90]. The
vasodilatatory response to adenosine is increased in cirrhosis
due to a higher expression of the adenosine A1 receptor in hep-
atic arteries of cirrhotic livers [91]. Since this receptor leads to
an increased production of NO it can be postulated that both, ade-
nosine and NO are involved in the reduced vascular resistance of
the hepatic arteries in the cirrhotic livers [91].
On the other hand, the higher amount of pro-angiogenic fac-
tors present in cirrhosis lead also to a neo-angiogenesis of arterial
vessels. Indeed, the presence of neo-angiogenesis of arterial ves-
sels in cirrhosis has been demonstrated in two different animal
models [89]. However, the mechanisms that are involved in this
arterial neo-angiogenesis, so far, have not been investigated. Fur-
thermore, it has been shown that the vessel wall of the hepatic
artery undergoes morphological changes in cirrhosis [89]. This
process is called remodelling and the main anatomical change
is the decrease of the amount of smooth muscle cells [89]. This
results in a smaller vessel wall and an increase in the diameter
of the vessel. Furthermore, due to the smaller amount of smooth
muscle cells the vasoconstrictive property of the vessel is
decreased.Areas for the future and new avenues for research
There are several areas where new advances are required, and to
some extent foreseen. With regards to therapeutic applications it
is likely that we will witness the advent of new treatment mod-
alities based on the use of agents reducing and/or preventing the
increase in hepatic vascular resistance by acting on hepatic vas-
cular tone [12], etiological agents, ﬁbrogenesis [92], angiogenesis
[35,40], or in all of these. Most likely, these concepts will ﬁnd
their best application in early phases of portal hypertension,
where prevention of clinical decompensation (i.e., preventing
ascites, variceal bleeding, and encephalopathy) is a real possi-
bility. We have new and highly effective etiological treatments
to prevent or reverse the development of portal hypertension in
cirrhosis due to hepatitis B or C virus infection. Early treatment
also offers better possibilities for antiﬁbrotic treatments acting
either on the cause of cirrhosis (antivirals) or directly on ﬁbrosis
(anti-lysil oxidase 2 (L-LOX2) monoclonal antibodies, anti-oxi-
dants, obeticholic acid) will probably have a greater prospect
for effectively achieving regression of ﬁbrosis in early phases of
cirrhosis, rather than in advanced stages when a lot of collagen
cross-linking and avascular scar tissue have developed [93,94].
Therapies modifying hepatic vascular tone by acting on NO sig-
naling (i.e., by means of simvastatin) [19,39] are already under
clinical evaluation. Statins may further improve liver ﬁbrogenesis
in cirrhosis [38]. Preliminary results from a double-blind ran-
domized controlled trial suggest a survival beneﬁt in advanced
stages when simvastatin is administered on top of currently
available treatments [95]. The possibility of improving portal
hypertension by modifying the microbioma, endotoxaemia, and
its consequences is also close to clinical application.
Another area where we anticipate a marked progress is the
application of new concepts on disturbances in liver microcircula-
tionasadriving force forportalhypertension. In this regard the role
of the hepatic artery in maintaining high portal pressure during aS128 Journal of Hepatology 2015progressive hepatic portal ﬂow decrease should be investigated,
as well as new development of non-invasive tools to assess the
hepatic microcirculation in patients with cirrhosis [96].Financial support
This work was supported in part by grants from Instituto de
Salud Carlos III (ISCiii, PI13/00341) to JB and from NIH (DK
59615) to VS.Conﬂict of interest
JB is a consultant for Gilead, Connatus, ONO-UK, Exallenz, Inter-
cept and Falk. RJG is a consultant for Gilead. VS has nothing to
disclose.
References
[1] Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The
burden of liver disease in Europe: a review of available epidemiological data.
J Hepatol 2013;58:593–608.
[2] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in
cirrhosis. N Engl J Med 2010;362:823–832.
[3] Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R,
et al. Beta-blockers to prevent gastroesophageal varices in patients with
cirrhosis. N Engl J Med 2005;353:2254–2261.
[4] Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al.
Hemodynamic events in a prospective randomized trial of propranolol
versus placebo in the prevention of a ﬁrst variceal hemorrhage. Gastroen-
terology 1990;99:1401–1407.
[5] Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J.
Hemodynamic response to pharmacological treatment of portal hyperten-
sion and long-term prognosis of cirrhosis. Hepatology 2003;37:902–908.
[6] Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG
measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol
2009;6:573–582.
[7] D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient
reduction and prevention of variceal bleeding in cirrhosis: a systematic
review. Gastroenterology 2006;131:1611–1624.
[8] Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A,
Bosch J. Pharmacological reduction of portal pressure and long-term risk of
ﬁrst variceal bleeding in patients with cirrhosis. Am J Gastroenterol
2006;101:506–512.
[9] Groszmann R, Kotelanski B, Cohn JN, Khatri IM. Quantitation of portasys-
temic shunting from the splenic and mesenteric beds in alcoholic liver
disease. Am J Med 1972;53:715–722.
[10] Kotelanski B, Groszmann RJ, Cohn JN. Circulation times in the splanchnic and
hepatic beds in alcoholic liver disease. Gastroenterology 1972;63:102–111.
[11] Berzigotti A, Bosch J. Pharmacologic management of portal hypertension.
Clin Liver Dis 2014;18:303–317.
[12] Bosch J, Abraldes JG, Groszmann RJ. Current management of portal
hypertension. J Hepatol 2003;38:S54–S68.
[13] Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol – A medical
treatment for portal hypertension? Lancet 1980;2:180–182.
[14] Bathal PS, Grossmann HJ. Reduction of the increased portal vascular
resistance of the isolated perfused cirrhotic rat liver by vasodilators. J
Hepatol 1985;1:325–329.
[15] Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and
decreased production of nitric oxide in the intrahepatic microcirculation of
cirrhotic rats. Hepatology 1998;28:926–931.
[16] Rockey DC, Housset CN, Friedman SL. Activation-dependent contractility of
rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993;92:1795–1804.
[17] Graupera M, Garcia-Pagan JC, Titos E, Claria J, Massaguer A, Bosch J, et al. 5-
lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic
rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology
2002;122:387–393.
[18] Graupera M, Garcia-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola
H, et al. Cyclooxygenase-derived products modulate the increased intra-
hepatic resistance of cirrhotic rat livers. Hepatology 2003;37:172–181.vol. 62 j S121–S130
JOURNAL OF HEPATOLOGY
[19] Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H,
Garcia-Pagan JC, et al. Simvastatin treatment improves liver sinusoidal
endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007;46:1040–1046.
[20] De Gottardi A, Berzigotti A, Seijo S, D’Amico M, Abraldes JG, Garcia-Pagan JC,
et al. Dark chocolate attenuates the post-prandial increase in HVPG in
patients with cirrhosis and portal hypertension., 52 ed.; 2010. p. S9.
[21] Hernandez-Guerra M, Garcia-Pagan JC, Turnes J, Bellot P, Deulofeu R,
Abraldes JG, et al. Ascorbic acid improves the intrahepatic endothelial
dysfunction of patients with cirrhosis and portal hypertension. Hepatology
2006;43:485–491.
[22] Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, Bosch
J, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4
cirrhotic rats with portal hypertension. Gut 2009;58:118–125.
[23] Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Colomer D, Fernandez M, Bosch
J, et al. The eNOS cofactor tetrahydrobiopterin improves endothelial
dysfunction in livers of rats with CCl4 cirrhosis. Hepatology 2006;44:44–52.
[24] Rosado E, Rodriguez-Vilarrupla A, Gracia-Sancho J, Tripathi D, Garcia-
Caldero H, Bosch J, et al. Terutroban, a TP-receptor antagonist, reduces portal
pressure in cirrhotic rats. Hepatology 2013;58:1424–1435.
[25] Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal
NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J
Clin Invest 2000;105:741–748.
[26] Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC,
et al. Simvastatin enhances hepatic nitric oxide production and decreases
the hepatic vascular tone in patients with cirrhosis. Gastroenterology
2004;126:749–755.
[27] DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal
endothelial cell phenotype is maintained by paracrine and autocrine
regulation. Am J Physiol Gastrointest Liver Physiol 2004;287:G757–G763.
[28] DeLeve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate
cell activation and promote reversion to quiescence. Hepatology
2008;48(3):920–930.
[29] Marrone G, Russo L, Rosado E, Hide D, Garcia-Cardena G, Garcia-Pagan JC,
et al. The transcription factor KLF2 mediates hepatic endothelial protection
and paracrine endothelial-stellate cell deactivation induced by statins. J
Hepatol 2013;58:98–103.
[30] Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages)
where before there was one: In search of a pathophysiological classiﬁcation
of cirrhosis. Hepatology 2010;51:1445–1449.
[31] Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and
portal vein thrombosis in cirrhosis: possible role in development of
parenchymal extinction and portal hypertension. Hepatology 1995;21:
1238–1247.
[32] Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin
prevents portal vein thrombosis and liver decompensation in patients with
advanced cirrhosis. Gastroenterology 2012;143:1253–1260.
[33] Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease
and cirrhosis – Current status and future directions. J Hepatol
2014;61:912–924.
[34] Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann
RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide
modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100:
2923–2930.
[35] Thabut D, Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in
chronic liver disease: new targets for the treatment of portal hypertension? J
Hepatol 2010;53:976–980.
[36] Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and
Decreased Production of Nitric Oxide in the intrahepatic microcirculation of
cirrhotic rats. Hepatology 1998;28:926–931.
[37] Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al.
Impaired endothelial nitric oxide synthase activity associated with
enhanced caveolin binding in experimental cirrhosis in the Rat. Gastroen-
terology 1999;117:1222–1228.
[38] Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, et al.
Atorvastatin attenuates hepatic ﬁbrosis in rats after bile duct ligation via
decreased turnover of hepatic stellate cells. J Hepatol 2010;53:702–712.
http://dx.doi.org/10.1016/j.jhep.2010.04.025.
[39] Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al.
Simvastatin lowers portal pressure in patients with cirrhosis and portal
hypertension: a randomized controlled trial. Gastroenterology 2009;136:
1651–1658.
[40] Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in
liver disease. J Hepatol 2009;50:604–620.
[41] Thabut D, Moreau R, Lebrec D. Noninvasive assessment of portal hyperten-
sion in patients with cirrhosis. Hepatology 2011;53:683–694.Journal of Hepatology 2015[42] Ding BS, Nolan DJ, Butler JM, James D, Babazadeh AO, Rosenwaks Z, et al.
Inductive angiocrine signals from sinusoidal endothelium are required for
liver regeneration. Nature 2010;468:310–315.
[43] Ding BS, Cao Z, Lis R, Nolan DJ, Guo P, Simons M, et al. Divergent angiocrine
signals from vascular niche balance liver regeneration and ﬁbrosis. Nature
2014;505:97–102.
[44] Novo E, Cannito S, Zamara E, Valfre di BL, Caligiuri A, Cravanzola C, et al.
Proangiogenic cytokines as hypoxia-dependent factors stimulating migra-
tion of human hepatic stellate cells. Am J Pathol 2007;170:1942–1953.
[45] Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al. Vascular
endothelial growth factor promotes ﬁbrosis resolution and repair in mice.
Gastroenterology 2014;146:1339–1350.
[46] DeLeve LD. Liver sinusoidal endothelial cells in hepatic ﬁbrosis. Hepatology
2014. http://dx.doi.org/10.1002/hep.27376, [Epub ahead of print].
[47] Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, et al.
Angiotensin II induces contraction and proliferation of human hepatic
stellate cells. Gastroenterology 2000;118:1149–1156.
[48] Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver.
Gastroenterology 2006;130:1886–1900.
[49] Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, et al. Intestinal
decontamination inhibits TLR4 dependent ﬁbronectin-mediated cross-talk
between stellate cells and endothelial cells in liver ﬁbrosis in mice. J Hepatol
2012;56:893–899.
[50] Jagavelu K, Routray C, Shergill U, O’Hara SP, Faubion W, Shah VH. Endothelial
cell toll-like receptor 4 regulates ﬁbrosis-associated angiogenesis in the
liver. Hepatology 2010;52:590–601.
[51] Seki E, De MS, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4
enhances TGF-beta signaling and hepatic ﬁbrosis. Nat Med 2007;13:
1324–1332.
[52] Seo YS, Kwon JH, Yaqoob U, Yang L, De Assuncao TM, Simonetto DA, et al.
HMGB1 recruits hepatic stellate cells and liver endothelial cells to sites of
ethanol-induced parenchymal cell injury. Am J Physiol Gastrointest Liver
Physiol 2013;305:G838–G848.
[53] Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, et al.
Inﬂammation and portal hypertension – The undiscovered country. J
Hepatol 2014;61:155–163. http://dx.doi.org/10.1016/j.jhep.2014.03.01.
[54] Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of
variant ﬁbronectins in wound healing: cellular source and biological activity
of the EIIIA segment in rat hepatic ﬁbrogenesis. J Cell Biol 1994;127:
2037–2048.
[55] Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial
cell migration through beta1 integrin and Src-dependent phosphorylation of
ﬁbroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol
Chem 2012;287:7190–7202.
[56] Northup PG, Intagliata NM. Anticoagulation in cirrhosis patients: what don’t
we know? Liver Int 2011;31:4–6.
[57] Simonetto DA, Yang HY, Yin M, deAssuncao TM, Kwon JH, Hilsher M, et al.
Chronic passive venous congestion drives hepatic ﬁbrogenesis via sinusoidal
thrombosis and mechanical forces. Hepatology 2014;61(2):648–659.
[58] Garcia-Pagan JC, Shah VH. Microparticles and paracrine signaling in portal
hypertension: crucial conversations or idle chat? Gastroenterology
2012;143:22–25.
[59] Rautou PE, Bresson J, Sainte-Marie Y, Vion AC, Paradis V, Renard JM, et al.
Abnormal plasma microparticles impair vasoconstrictor responses in
patients with cirrhosis. Gastroenterology 2012;143:166–176.
[60] Witek RP, Yang L, Liu R, Jung Y, Omenetti A, Syn WK, et al. Liver cell-derived
microparticles activate hedgehog signaling and alter gene expression in
hepatic endothelial cells. Gastroenterology 2009;136:320–330.
[61] Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A,
et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-
Alpha1-adrenergic activity, has a greater portal hypotensive effect than
propranolol in patients with cirrhosis. Hepatology 1999;30:79–83.
[62] Bosch J. Carvedilol for portal hypertension in patients with cirrhosis.
Hepatology 2010;51:2214–2218.
[63] Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC,
et al. Multicenter randomized controlled trial of carvedilol versus variceal
band ligation for the prevention of the ﬁrst variceal bleed. Hepatology
2007;46:269A.
[64] Kowalski HJ, Abelman WH. The cardiac output at rest in Laennec cirrhosis. J
Clin Invest 1953;32:1025–1033.
[65] Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later:
pathophysiology and clinical consequences. Hepatology 1994;20:
1359–1363.
[66] Guyton AC. Arterial pressure and hypertension. Philadelphia: WB Saunders;
1980.vol. 62 j S121–S130 S129
Review
[67] Moreno AH, Burchell AR, Rousselot LM, Panke WF, Slafsky F, Burke JH. Portal
blood ﬂow in cirrhosis of the liver. J Clin Invest 1967;46:436–445.
[68] Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J
Clin Gastroenterol 2005;39(4 Suppl 2):S125–S130.
[69] Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and
mechanisms involved in its maintenance in a rat model. Am J Physiol
1985;248:G618–G625.
[70] Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood ﬂow through the
portal system in cirrhotic rats. Gastroenterology 1984;87:1120–1123.
[71] Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal
hypertension: too much, not enough. Hepatology 2002;35:478–491.
[72] Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ.
Mild increases in portal pressure upregulate vascular endothelial growth
factor and endothelial nitric oxide synthase in the intestinal microcircula-
tory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver
Physiol 2006;290:G980–G987.
[73] Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N omega-
nitro-L-arginine ameliorates portal-systemic shunting in portal-hyperten-
sive rats. Gastroenterology 1993;105:1464–1470.
[74] Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, et al.
Activation of the MAS receptor by angiotensin-(1–7) in the renin-an-
giotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroen-
terology 2013;145:874–884.
[75] Fernandez M. Molecular pathophysiology of portal hypertension. Hepa-
tology 2014. http://dx.doi.org/10.1002/hep.27343, [Epub ahead of print].
[76] Mehta G, Gustot T, Mookerjee RP, Garcia-Pagan JC, Fallon MB, Shah VH, et al.
Inﬂammation and portal hypertension - the undiscovered country. J Hepatol
2014;61:155–163.
[77] Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF
receptor-2 monoclonal antibody prevents portal-systemic collateral vessel
formation in portal hypertensive mice. Gastroenterology 2004;126:886–894.
[78] Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical
applications of research on angiogenesis. N Engl J Med 1995;333:
1757–1763.
[79] Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, et al.
Disruption of negative feedback loop between vasohibin-1 and vascular
endothelial growth factor decreases portal pressure, angiogenesis, and
ﬁbrosis in cirrhotic rats. Hepatology 2014;60:633–647.
[80] Rigau J, Bosch J, Bordas JM, Navasa M, Mastai R, Kravetz D, et al. Endoscopic
measurement of variceal pressure in cirrhosis: correlation with portal
pressure and variceal hemorrhage. Gastroenterology 1989;96:873–880.
[81] Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J.
Reversal of portal hypertension and hyperdynamic splanchnic circulation by
combined vascular endothelial growth factor and platelet-derived growth
factor blockade in rats. Hepatology 2007;46:1208–1217.
[82] Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneﬁcial
effects of sorafenib on splanchnic, intrahepatic, and portocollateral circula-S130 Journal of Hepatology 2015tions in portal hypertensive and cirrhotic rats. Hepatology 2009;49:
1245–1256.
[83] Escorsell A, Bordas JM, Feu F, Garcia-Pagan JC, Gines A, Bosch J, et al.
Endoscopic assessment of variceal volume and wall tension in cirrhotic
patients: effects of pharmacological therapy. Gastroenterology 1997;113:
1640–1646.
[84] Tygstrup N, Winkler K, Mellemgaard K, Ndreassen M. Determination of the
hepatic arterial blood ﬂow and oxygen supply in man by clamping the
hepatic artery during surgery. J Clin Invest 1962;41:447–454.
[85] Greenway CV, Lawson AE, Stark RD. The effect of haemorrhage on hepatic
artery and portal vein ﬂows in the anesthetized cat. J Physiol
1967;193:375–379.
[86] Burchell AR, Moreno AH, Panke WF, Nealon Jr TF. Hepatic artery ﬂow
improvement after portacaval shunt: a single hemodynamic clinical corre-
late. Ann Surg 1976;184:289–302.
[87] Bredfeldt JE, Riley EM, Groszmann RJ. Compensatory mechanisms in
response to an elevated hepatic oxygen consumption in chronically
ethanol-fed rats. Am J Physiol 1985;248:G507–G511.
[88] Zipprich A, Loureiro-Silva MR, D’Silva I, Groszmann RJ. The role of hepatic
arterial ﬂow on portal venous and hepatic venous wedged pressure in the
isolated perfused CCl4-cirrhotic liver. Am J Physiol Gastrointest Liver Physiol
2008;295:G197–G202.
[89] Zipprich A, Loureiro-Silva MR, Jain D, D’Silva I, Groszmann RJ. Nitric oxide
and vascular remodeling modulate hepatic arterial vascular resistance in the
isolated perfused cirrhotic rat liver. J Hepatol 2008;49:739–745.
[90] Lautt WW, Legare DJ, d’Almeida MS. Adenosine as putative regulator of
hepatic arterial ﬂow (the buffer response). Am J Physiol 1985;248:
H331–H338.
[91] Zipprich A, Mehal WZ, Ripoll C, Groszmann RJ. A distinct nitric oxide and
adenosine A1 receptor dependent hepatic artery vasodilatatory response in
the CCl4-cirrhotic liver. Liver Int 2010;30:988–994.
[92] Lee UE, Friedman SL. Mechanisms of hepatic ﬁbrogenesis. Best Pract Res Clin
Gastroenterol 2011;25:195–206.
[93] Friedman SL, Bansal MB. Reversal of hepatic ﬁbrosis – Fact or fantasy?
Hepatology 2006;43:S82–S88.
[94] Hernandez-Gea V, Friedman SL. Pathogenesis of liver ﬁbrosis. Annu Rev
Pathol 2011;6:425–456.
[95] Abraldes JG, Villanueva C, Aracil C, Turnes J, Hernandez-Guerra M, Genesca J,
et al. Addition of simvastatin to standard treatment improves survival after
variceal bleeding in patients with cirrhosis. A double-blind randomized
trial., 60 ed.; 2014. p. S525.
[96] Amat-Roldan I, Berzigotti A, Gilabert R, Bosch J. Assessment of hepatic
vascular network connectivity by automated graph analysis of dynamic
contrast enhanced ultrasound to evaluate portal hypertension in patients
with cirrhosis: a pilot study. Radiological society of North America 2014
scientiﬁc assembly and annual meeting, November 30-December 5, 2014,
Chicago, IL:VSGI21-05.vol. 62 j S121–S130
